European Commission

Blood cancer
#Cell therapy #CHMP #European Commission #Haematology #Oncology #Stem cells

Stem cell therapy gets positive CHMP opinion for blood cancers

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending granting conditional marketing authorisation for Zemcelpro (UM171 cell therapy).  The positive opinion relates to the treatment of adults with haematological malignancies requiring an allogeneic haematopoietic stem cell transplantation following… Read More

#News #Regulatory

Leukaemia
#AstraZeneca #Blood cancer #European Commission #Leukaemia #Oncology

Fixed-duration Calquence-based regimens approved in EU

A fixed-duration regimen of AstraZeneca’s BTK inhibitor Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, has been approved in the European Union (EU) for previously untreated chronic lymphocytic leukaemia (CLL).  The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human… Read More

#News #Regulatory

#DDW Highlights podcast #European Commission #FDA #Regulatory

New DDW Highlights podcast: 19 May 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Our news highlights this time focus on two major regulatory agencies, in a week… Read More

#News

#European Commission #FDA #Regulatory

This week in drug discovery (12-16 May) 

News round-up for 12-16 May by DDW Senior Digital Content Editor Diana Spencer. Our news highlights this time focus on two major regulatory agencies, in a week that saw the European Commission (EC) launch a new fund designed to tempt US researchers to EU countries, and the US… Read More

#News

Lung cancer
#European Commission #Lung cancer #Monoclonal antibodies #Oncology

European Commission approves Tevimbra for small cell lung cancer

The European Commission has approved Tevimbra (tislelizumab), in combination with etoposide and platinum chemotherapy, as a first-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC).  The new indication is based on results of RATIONALE-312 study, which demonstrated statistically significant overall survival benefit for patients treated with Tevimbra… Read More

#News #Regulatory

Monoclonal antibody
#Crohn's disease #European Commission #Inflammatory Bowel Disease #Johnson & Johnson #Monoclonal antibodies

New EU approval for Johnson & Johnson’s guselkumab

The European Commission (EC) has approved Tremfya (guselkumab), the first dual-acting IL-23 inhibitor offering both subcutaneous (SC) and intravenous (IV) induction options, for adult patients with moderately to severely active Crohn’s disease.  The approval is based on data which showed that guselkumab induction therapy administered either intravenously (GALAXI 2 and… Read More

#News #Regulatory

EU flag
#European Commission #European Union #Funding #Research and development

EC urges researchers to “choose Europe for science”

European Commission President Ursula von der Leyen has announced new funding ‘super grants’ at the ‘Choose Europe for Science’ conference.  The substantial additional budget for the development of larger, longer-term grants has been welcomed by the Scientific Council of the European Research Council (ERC).   As… Read More

#News #Trending News

Map of Europe
#AstraZeneca #European Commission #Lymphoma #Oncology #Phase III trial

Calquence plus chemoimmunotherapy approved in the EU

AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been approved in the European Union (EU) for previously untreated mantle cell lymphoma (MCL).  It is approved in patients who are not eligible for autologous stem cell transplant.  The approval by the European Commission was based on positive results from… Read More

#News #Regulatory

ulcerative colitis
#European Commission #Johnson & Johnson #Monoclonal antibodies #Ulcerative colitis (UC)

Guselkumab approved in the EU for ulcerative colitis

The European Commission (EC) has approved a marketing authorisation (MA) for Johnson & Johnson’s Tremfya (guselkumab) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).  It is approved in patients who had an inadequate response, lost response, or were intolerant to either conventional therapy or… Read More

#News #Regulatory

Lecanemab
#Alzheimer's #Biogen #Eisai #European Commission #Monoclonal antibodies #Neuroscience

Lecanemab gets EU approval in early Alzheimer’s

The European Commission (EC) has granted Leqembi (lecanemab) Marketing Authorisation (MA) in the European Union (EU).  The approval makes the medicine the first therapy that targets an underlying cause of Alzheimer’s disease (AD) to be granted a MA in the EU.  Lecanemab is indicated for the treatment of adult patients… Read More

#News #Regulatory #Trending News

#3D modelling #Artificial intelligence (AI) #European Commission #Monoclonal antibodies #Oncology #Solid tumours

This week in drug discovery (7-11 April) 

News round-up for 7-11 April by DDW Senior Digital Content Editor Diana Spencer. As the political news brings more uncertainty for the sector, this week we are focusing on positive developments in the field of oncology, from the possibilities of cancer cures in the rainforest, to a new… Read More

#News

Map of Europe
#EFPIA #European Commission #Investment #Pharmaceutical industry #Survey

European pharma CEOs threaten exodus to the US

CEOs of the research-based pharmaceutical industry have issued a stark warning to the European Commission that unless Europe delivers rapid, radical policy change then pharmaceutical research, development and manufacturing is increasingly likely to be directed towards the US.  A survey of European Federation of Pharmaceutical Industries and Associations (EFPIA) member… Read More

#Business & Investment #News #Trending News

European Commission
#European Commission #Johnson & Johnson #Monoclonal antibodies #Oncology

EC approves subcutaneous use of J&J antibodies for cancer

The European Commission (EC) has approved an indication extension for two of Johnson & Johnson’s monoclonal antibody therapies in oncology.  The approval of Darzalex (daratumumab) has been extended to include a subcutaneous (SC) formulation in the frontline setting in combination with bortezomib, lenalidomide, and dexamethasone (daratumumab-VRd) for newly diagnosed multiple… Read More

#News #Regulatory

Hormones in the brain concept
#European Commission #Lundbeck #Neuroscience #Otsuka #Schizophrenia

Brexpiprazole’s EU approval extended to include adolescents

The European Commission (EC) has approved Otsuka’s Rxulti (brexpiprazole) for the treatment of schizophrenia in adolescents aged 13 years and older.  The drug was previously approved in the European Union in 2018 for the treatment of schizophrenia in adults.  The EC based its approval on a six-week trial of 316… Read More

#News #Regulatory

Monoclonal antibodies
#CSL #European Commission #Monoclonal antibodies #Rare disease

EC approves antibody to prevent hereditary angioedema attacks

The European Commission (EC) has approved Andembry (garadacimab), the only once-monthly treatment targeting factor XIIa to prevent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older.  Andembry inhibits plasma protein factor XIIa, which initiates the cascade of events leading to angioedema at various sites… Read More

#News #Regulatory

The European Medicines Agency in Amsterdam
#European Commission #Monoclonal antibodies #Myeloma #Oncology #Sanofi

EU extends Sarclisa use to newly diagnosed multiple myeloma

Following the adoption of a positive opinion by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), the EU has now approved Sanofi’s monoclonal antibody Sarclisa (isatuximab).  It is approved in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult… Read More

#News #Regulatory